Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Graphene to Fight Antimicrobial Resistance

Project description

Optimising our weapons against antimicrobial obstruction

Fighting the crisis of antimicrobial resistance as a serious cause of mortality in the European Union requires quicker, more flexible and efficient techniques. The EU-funded GRAPHFITI project will introduce an innovative approach to antimicrobial susceptibility testing technologies using graphene to address the drug-resistant pathogens threat. As a continuation of the EU-funded ENIGMA research project, GRAPHFITI will validate the use of graphene membranes for probing nanomechanical motion of bacterial cells. Moreover, the project will enable utilising atomically thin membranes with single bacterial cell sensitivity, revolutionising the diagnostic toolkit for the rapid point-of-care screening of antimicrobial resistance.

Objective

Today, antimicrobial resistance is emerging as a global burden, endangering our lives. Drug-resistant pathogens kill about 25,000 infected people solely in the European Union every year. In the fight against this crisis, rapid Antimicrobial Susceptibility Testing (AST) plays a crucial role. Although effective in discerning the right concentration of antibiotics required to inhibit the growth of a pathogen, conventional AST techniques are not fit for point-of-care, since they are slow and require large microbial inocula.
The advent of graphene, and the ability to fabricate one-atom thick membranes, has made it possible to make miniaturised sensors that are extremely sensitive to nanoscale forces. During the research project ENIGMA carried out in the framework of the ERC Starting Grant no. 802093, we have developed a methodology that can probe nanomechanical motion of graphene membranes in the presence of bacterial cells. Here, I propose to further validate this technology and realize a proof-of-concept demonstrator that offers automated high throughput AST using massively parallelized graphene membranes. By eliminating the need for culturing large number of bacterial cells, GRAPHFITI has the potential to shift the current paradigm of AST technologies towards the use of atomically thin membranes with single bacterial cell sensitivity, thus enabling diagnostic tools for fast point-of-care screening of antimicrobial resistance.

Keywords

Programme(s)

Topic(s)

Funding Scheme

ERC-POC - Proof of Concept Grant

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2020-PoC

See all projects funded under this call

Host institution

TECHNISCHE UNIVERSITEIT DELFT
Net EU contribution
€ 150 000,00
Total cost
No data

Beneficiaries (1)